Back to News
Market Impact: 0.3
Ernexa Reports Positive ERNA-101 Safety Data Ahead Of Q4 IND
Source: Nasdaq
Healthcare & Biotech
Ernexa Therapeutics reported positive results from three IND-enabling safety studies of ERNA-101, its investigational induced mesenchymal stromal cell (iMSC) therapy for advanced cancers. The data support advancement toward an IND filing, representing a positive clinical-development catalyst for ERNA, though no efficacy or financial details were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
ERNA0.85
More News
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Some Oura IPO Investors Were Said to Push Back Citing Valuation
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data